 | SCS Ventures is investing in
including innovative mechanisms of action and drug repositioning
(QSAR or CM&S Good Simulation Practice compliant)
& overall Life Sciences |
Investment focus
SCS Ventures is the investment arm of Socosur Chem, still fully family-owned Paris-based group founded in 1990.
Built by entrepreneurs, we invest with the mindset of industrial Pharma keen to Biotech innovation, not financial engineers.
For more than a decade, we have been active in private equity, supporting founders who build transformative companies in biotech industry,
not to mention the fast-growing field of in silico Regulatory expertise.
Our differentiated strength: deep operational experience in regulated life sciences, combined with a global footprint.
What We Do Invest into
We support ambitious founders from Proof of Concept approved to GMP scale-up
by providing strategic guidance and targeted private investments (up to Series A level).
Our primary areas of focus include:
|  |  |
| Biotech First-in-Class | In-silico Toxicology | Internationalisation |
| Drug repositionning and novel mechanisms of action from Proof of Concept to GMP scale-up | QSAR, CM&S, GSP and next-generation approach methods (NAMs) for Regulatory derisking | Cross border expansion and phartnership developments for Life Science companies |
Our MissionTo leverage our multidisciplinary expertise in pharmaceutical operations, regulatory pathways, toxicology, and global expansion to help tomorrow’s leaders navigate their most critical phases of growth. Our hands-on, responsible investment approach is designed to create long-term, sustainable value for the companies we support as well as the scientific and financial ecosystems around them. |
CM&S Momentum
from in silico Computational Modeling & Simulation to more successful first in class Biotech companies
Across multiple ventures, our team has guided founders through decisive strategic and operational milestones.
The lessons learned from our own entrepreneurial history from the foundation of the support we provide today.
 | "SCS Ventures is more and more designed to invest in the candidates shaping the future of next Biotech true innovators with new Computational & Modeling technologies and all the regulatory toxicology derisking of such candidates."
Matthieu Chareyre, President of SCS Ventures |
Our Investment Philosophy
We partner with founders at their most decisive stages from Proof of Concept up to Series A providing capital, strategic insight, and hands-on involvement |  |
Our approach is guided by three principles:
Entrepreneurial Alignment We have founded, scaled, and exited companies ourselves. We invest with the same discipline, urgency, and accountability we expect from our past investment partners. | |
| Strategic Value Creation We specialize in unlocking international growth, navigating complex regulatory landscapes, while structuring robust scientific and commercial strategies. | |
| Long-Term Partnership Our objective is lasting value creation for founders, employees, investors, and the pharmaceutical industry ecosystems we contribute to. |
Sector Focus
We invest where our expertise and networks create the strongest advantage:
- Biotech platforms & drug development technologies
- Pharmaceutical or veterinary innovative mechanism of action innovation
- Computational & in-silico toxicology (NAM, QSAR, CM&S, GSP)
- Internationally cross-border science-driven companies
 | What We Bring Beyond CapitalWe support portfolio companies through:
|
To ensure full accessibility for current and prospective investors, SCS Ventures actively participates in major global investor events
and maintains a presence across the established communication and scheduling systems used by leading institutional investors.
For US based companies, please note that you can benefit from our Gold Supplier Partnership with Scientist.com, a streamlined, AI powered R&D procurement platform.
If your company is based in India, you can benefit from simplified tax filing and ensured regulatory compliance thanks to our PAN card registration.